SEC Company Response from Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX) — Jul 27, 2016
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: July 27, 2016 · CIK: 0001671502 · Accession: 0001144204-16-114742
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212432
Referenced dates: July 12, 2016
Letter
Division of Corporation Finance United States Securities and Exchange Commission Re: Cellect Biotechnology Ltd. (the “Company”) Amendments Nos. 1, 2 and 3 to Registration Statement on Form F-1 Filed July 22, 2016, July 25, 2016 and July 26, 2016 File No. 333-212432
Dear Ms. Hayes:
The purpose of this letter is to respond to your letter of July 27, 2016, with respect to the above-captioned filing. Concurrently with this letter the Company is submitting an amendment to its Registration Statement on Form F-1 (the “Filing”). For ease of reference, the Company’s responses are keyed to your comments (inserted in italicized font).
Amendment No. 1 filed July 22, 2016
Business
Apotainer Selection Kit, page 66
1. We note your response to comment 1 from our letter dated July 12, 2016 and the revisions made in response to our comment. Additionally, we note that the BIRD Foundation’s website, the BIRD model calls for repayments of 5% of each dollar reported as sales revenue from sales of the product or subsequent products based on the technology developed in the project; 30% from extending licensing rights; or 50% of the revenue earned from the sale of the technology to a third party. Additionally, the website states that BIRD is entitled to repayments of up to 150% of the conditional grant. Please revise your disclosure to provide this additional information or tell us the basis of your belief that the BIRD Foundation will revise its program with respect to your grant.
Response to Comment 1:
The Company has amended the disclosure on page 66 of the Filing with respect to the BIRD Foundation grant to provide the terms of the typical BIRD Foundation model.
Ms. Suzanne Hayes
Page 2
July 27, 2016
Amendment No. 2 filed July 25, 2016
Dilution, page 43
2. Please provide us your computation of $3.90 pro forma net tangible book value per ADS, as adjusted to give effect to this offering.
Response to Comment 2:
The Company has revised the pro forma net tangible book value per ADS, as adjusted to give effect to this offering, from $3.90 to $2.32 and has revised the disclosures contained on page 43 of the Filing.
Amendment No. 3 filed July 26, 2016
Exhibit 5.1
3. Please revise your legal opinion to provide an opinion with respect to the warrants.
Response to Comment 3:
The Company has revised the legal opinion contained in Exhibit 5.1 to provide an opinion with respect to the warrants being included in the offering.
Please contact the undersigned at (+972) (9) 974-1444, or Oded Har-Even at (212) 660-5002 or Shy S. Baranov at (617) 338-2932, attorneys at Zysman, Aharoni, Gayer and Sullivan & Worcester LLP, the Company's U.S. counsel, if you have any questions or require additional information.
Respectfully,
Cellect Biotechnology Ltd.
Show Raw Text
CORRESP
1
filename1.htm
CELLECT BIOTECHNOLOGY LTD.
23 Hata’as Street
Kfar Saba, Israel 44425
July 27, 2016
Suzanne Hayes, Assistant Director
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-6010
Re: Cellect Biotechnology Ltd. (the “Company”)
Amendments Nos. 1, 2 and 3 to Registration Statement on Form F-1
Filed July 22, 2016, July 25, 2016 and July 26, 2016
File No. 333-212432
Dear Ms. Hayes:
The purpose of this
letter is to respond to your letter of July 27, 2016, with respect to the above-captioned filing. Concurrently with this letter
the Company is submitting an amendment to its Registration Statement on Form F-1 (the “Filing”). For ease of reference,
the Company’s responses are keyed to your comments (inserted in italicized font).
Amendment No. 1 filed July 22, 2016
Business
Apotainer Selection Kit, page 66
1. We note your response to comment 1 from our letter dated July 12, 2016 and the revisions made
in response to our comment. Additionally, we note that the BIRD Foundation’s website, the BIRD model calls for repayments
of 5% of each dollar reported as sales revenue from sales of the product or subsequent products based on the technology developed
in the project; 30% from extending licensing rights; or 50% of the revenue earned from the sale of the technology to a third party.
Additionally, the website states that BIRD is entitled to repayments of up to 150% of the conditional grant. Please revise your
disclosure to provide this additional information or tell us the basis of your belief that the BIRD Foundation will revise its
program with respect to your grant.
Response to Comment 1:
The Company has amended
the disclosure on page 66 of the Filing with respect to the BIRD Foundation grant to provide the terms of the typical BIRD Foundation
model.
Ms. Suzanne Hayes
Page 2
July 27, 2016
Amendment No. 2 filed July 25, 2016
Dilution, page 43
2. Please provide us your computation of $3.90 pro forma net tangible book value per ADS, as adjusted
to give effect to this offering.
Response to Comment 2:
The Company has revised the pro forma net
tangible book value per ADS, as adjusted to give effect to this offering, from $3.90 to $2.32 and has revised the disclosures contained
on page 43 of the Filing.
Amendment No. 3 filed July 26, 2016
Exhibit 5.1
3. Please revise your legal opinion to provide an opinion with respect to the warrants.
Response to Comment 3:
The Company has revised the legal opinion
contained in Exhibit 5.1 to provide an opinion with respect to the warrants being included in the offering.
Please contact the
undersigned at (+972) (9) 974-1444, or Oded Har-Even at (212) 660-5002 or Shy S. Baranov at (617) 338-2932, attorneys at Zysman,
Aharoni, Gayer and Sullivan & Worcester LLP, the Company's U.S. counsel, if you have any questions or require additional information.
Respectfully,
Cellect Biotechnology Ltd.
By: /s/ Dr. Shai Yarkoni
Dr. Shai Yarkoni
Chief Executive Officer
cc: Oded Har-Even, Esq.
Shy S. Baranov, Esq.